{"id":2923,"date":"2006-10-07T10:44:27","date_gmt":"2006-10-07T09:44:27","guid":{"rendered":"http:\/\/moomango.co.uk\/htb\/?p=2923"},"modified":"2013-12-06T16:02:49","modified_gmt":"2013-12-06T16:02:49","slug":"gilead-licenses-tenofovir-to-indian-generic-manufacturers","status":"publish","type":"post","link":"https:\/\/i-base.info\/htb\/2923","title":{"rendered":"Gilead licenses tenofovir to Indian generic manufacturers"},"content":{"rendered":"<p><strong>On 22 September 2006, Gilead Sciences announced that it had signed new non-exclusive agreements with generic manufacturers in India, to produce and distribute generic versions of tenofovir disoproxil fumarate (tenofovir DF) to 95 low-income countries around the world, including India.<\/strong><\/p>\n<p>Affordable tenofovir is one on the treatment most in demand both for second-line therapy, and more tolerable first-line treatment.<\/p>\n<p>The generic companies are Alkem Laboratories, Aurobindo Pharma, J.B. Chemicals &amp; Pharmaceuticals, Matrix Laboratories, Medchem International, Ranbaxy Laboratories and Shasun Chemicals &amp; Drugs. In August, Gilead announced similar agreements with India-based Emcure Pharmaceuticals, Hetero Drugs and Strides Arcolab.<\/p>\n<p>The license agreements require that the generic companies meet certain national and international regulatory standards and include a technology transfer to enable expeditious production of large volumes of high-quality generic versions of tenofovir DF. In addition, these agreements allow the manufacture of commercial quantities of both active pharmaceutical ingredient (API) and finished product.<\/p>\n<p>Source: Gilead press release<\/p>\n","protected":false},"excerpt":{"rendered":"<p>On 22 September 2006, Gilead Sciences announced that it had signed new non-exclusive agreements with generic manufacturers in India, to produce and distribute generic versions of tenofovir disoproxil fumarate (tenofovir DF) to 95 low-income countries around the world, including India. &hellip;<\/p>\n","protected":false},"author":4,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[38],"tags":[],"class_list":["post-2923","post","type-post","status-publish","format-standard","hentry","category-treatment-access"],"_links":{"self":[{"href":"https:\/\/i-base.info\/htb\/wp-json\/wp\/v2\/posts\/2923","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/i-base.info\/htb\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/i-base.info\/htb\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/i-base.info\/htb\/wp-json\/wp\/v2\/users\/4"}],"replies":[{"embeddable":true,"href":"https:\/\/i-base.info\/htb\/wp-json\/wp\/v2\/comments?post=2923"}],"version-history":[{"count":0,"href":"https:\/\/i-base.info\/htb\/wp-json\/wp\/v2\/posts\/2923\/revisions"}],"wp:attachment":[{"href":"https:\/\/i-base.info\/htb\/wp-json\/wp\/v2\/media?parent=2923"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/i-base.info\/htb\/wp-json\/wp\/v2\/categories?post=2923"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/i-base.info\/htb\/wp-json\/wp\/v2\/tags?post=2923"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}